A new Phase 1B/2 trial treated patients with acute myeloid leukemia (AML) in a drug regimen combination of Annamycin and Ara-C. The evaluation of Annamycin in combination with Ara-C (cytarabine) has ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
Stocktwits on MSN
SLS stock tests $5 again: Retail targets 'no' vote on 20M share dilution push before AML trial results
Investor focus shifted toward a shareholder vote on a proposal to expand the company’s incentive share pool by 20 million shares. ・CEO Angelos Stergiou urged investors to support the expansion, ...
LAVAL, QC, April 21, 2026 /CNW/ - In recognition of AML World Awareness Day, Servier Canada is highlighting the progress made in precision medicine for Acute Myeloid Leukemia (AML). With TIBSOVO(R) ...
Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...
SELLAS Life Sciences reports successful Phase 2 trial results for SLS009 in relapsed/refractory AML, exceeding response and survival rates. SELLAS Life Sciences Group has announced that its Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results